- Previous Close
32.74 - Open
32.60 - Bid 33.12 x 600
- Ask 33.26 x 300
- Day's Range
31.76 - 33.50 - 52 Week Range
24.34 - 73.80 - Volume
4,152,402 - Avg. Volume
3,327,634 - Market Cap (intraday)
4.129B - Beta (5Y Monthly) 0.87
- PE Ratio (TTM)
-- - EPS (TTM)
-2.03 - Earnings Date Feb 25, 2025 - Mar 3, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
45.75
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
www.apellis.comRecent News: APLS
View MorePerformance Overview: APLS
Trailing total returns as of 12/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: APLS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: APLS
View MoreValuation Measures
Market Cap
4.13B
Enterprise Value
4.20B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.71
Price/Book (mrq)
17.41
Enterprise Value/Revenue
5.88
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-34.97%
Return on Assets (ttm)
-16.23%
Return on Equity (ttm)
-106.56%
Revenue (ttm)
715.22M
Net Income Avi to Common (ttm)
-250.1M
Diluted EPS (ttm)
-2.03
Balance Sheet and Cash Flow
Total Cash (mrq)
403.69M
Total Debt/Equity (mrq)
198.40%
Levered Free Cash Flow (ttm)
-140.21M